Cited by 48Cervical Cancer and HPV ResearchWomen's cancer prevention and managementGlobal Cancer Incidence and Screening

A randomized, controlled trial of two strategies of offering the home‐based HPV self‐sampling test to non‐ participants in the Flemish cervical cancer screening program

Open access
Kellen, Eliane, Benoy, Ina, Vanden Broeck, Davy, Martens, Patrick, Bogers, Jean‐Paul, Haelens, Annemie, Van Limbergen, Erik·2018·International Journal of Cancer

Abstract

We conducted a randomized, controlled trial to evaluate different strategies of offering an HPV‐self sampling program, and compared this with two control groups. All total of 35,354 women who did not participate in the Flemish cancer screening program were included in the study: 9,118 received a HPV self‐collection brush (RIATOL qPCR HPV genotyping test (qPCR [E6/E7]); 9,098 were offered the opportunity to order an HPV‐selfsampling brush, 8,830 received the recall letter; 8,849 received no intervention. Within 12 months after the mailing, 18.7% of the women who had received the brush, participated by returning a self‐sample sample, while 10.6% women allocated to the opt‐ in group did so. 10.5% women who received the standard recall letter, had a PAP smear taken within a period of 12 months; while 8% women did so without receiving an intervention at all. Participation in postmenopausal women was higher than in women younger than 50 in both self‐sampling arms. Screening by means of the self‐sample kit increased by age, contradictory when screening is performed by a PAP smear. Of those testing hrHPV positive (9.5%), 88.9% attended for follow up cytology. The mean DNA concentration, found in the self‐sampler, decreased by age, causing a higher number of inconclusive results. Our results support the efficacy of a self‐sampling strategy to increase participation in the Flemish screening program. Self‐sampling seems particularly acceptable to postmenopausal non‐responders. Future research should focus on the performance of different self‐sampling devices in post‐menopausal women as low DNA concentrations exponentially increased over age.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.31391

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the Belgian randomized clinical trial, the response rate was 8.0% (95% CI 7.5% to 8.6%) in the control arm with no letter.

    “whereas in the second control arm (no letter), the response rate was slightly lower (8.0%, 95% confidence interval 7.5% to 8.6%)”

    From Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses (2018) · cites this paper as [69]

    The Participation section reports that 709 women (8%) in the no-intervention arm had a PAP smear within 12 months, and the study description identifies this as the second control group. Our copy does not report the claimed 95% confidence interval of 7.5%–8.6% for that rate; the Statistical analysis section discusses confidence intervals for odds ratios instead. Page numbers are not available for these passages. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • In the Belgian randomized clinical trial, the response rate was 10.5% (95% CI 9.9% to 11.2%) in the control arm with a reminder letter.

    “In the first control arm (reminder letter) the response rate was 10.5% (95% confidence interval 9.9% to 11.2%)”

    From Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses (2018) · cites this paper as [69]

    The Participation section reports that 931 of 8,830 women (10.5%) in the recall-letter control group had a Pap smear within 12 months. Our copy does not report the claimed 95% confidence interval of 9.9% to 11.2%, although it is consistent with the reported counts. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. BenoyIVBD SomersE BogersJ.Age stratified cellularity of Evalyn self‐collected cervical samples versus clinician‐taken samples. 31st International papillomavirus conference; 2017; Cape Town South Africa;2017.

Cited by

Sorted by citations

Authors
Kellen, E., Benoy, I., Vanden Broeck, D., Martens, P., Bogers, J., Haelens, A., & Van Limbergen, E.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • University of Antwerp (BE)
  • AML, Sonic Healthcare Antwerp Belgium
  • Centre for Cancer Detection Flanders Belgium
  • Belgian Cancer Registry, Saint‐Josse‐ten‐Noode Belgium
Corresponding author
Kellen, Eliane
Venue
International Journal of Cancer
Publisher
Wiley
Published
2018-04-10
Volume
143
Issue
4
Pages
861-868
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2832434163
Cited by
48
References
27
Citations by year
2026: 3 · 2025: 4 · 2024: 8 · 2023: 3 · 2022: 14 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 2
FWCI
3.12
Type
journal article
Language
en
Open access
Locations
  • International Journal of Cancer (publishedVersion)
  • PubMed (publishedVersion)
Funders
Flemish Government
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Keywords
HPV self-sampling, cervical cancer screening, screening uptake, non-participants, postmenopausal women, high-risk HPV, indeterminate results, DNA concentration
MeSH terms
Age Factors, Belgium, Uterine Cervical Neoplasms, DNA, Viral, Female, Humans, Mass Screening, Middle Aged, Patient Acceptance of Health Care, Self Care, Vaginal Smears, Papillomavirus Infections, Alphapapillomavirus, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review